Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).

被引：0
|
作者：
Sarkaria, Jann Nagina
Ballman, Karla V.
Kizilbash, Sani Haider
Sulman, Erik P.
Giannini, Caterina
Mashru, Sandeep H.
Piccioni, David Eric
Friday, Bret Edward Buckley
Dixon, Jesse G.
Kabat, Brian
Laack, Nadia N.
Hu, Leland
Kumthekar, Priya
Ellingson, Benjamin M.
Anderson, S. Keith
Galanis, Evanthia
机构：
[1] Mayo Clin, Rochester, MN USA
[2] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[3] Mayo Clin, Div Med Oncol, Rochester, MN USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] NW Kaiser Permanente, Portland, OR USA
[6] Univ Calif San Diego, Moores Canc Ctr, Ctr Personalized Canc Therapy, San Diego, CA USA
[7] Univ Calif San Diego, Moores Canc Ctr, Div Hematol & Oncol, San Diego, CA USA
[8] SMDC, Duluth, MN USA
[9] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[10] Mayo Clin, Phoenix, AZ USA
[11] Univ Chicago, Alliance Protocol Operat Off, Chicago, IL USA
[12] Univ Calif Los Angeles, Brain Res Inst, Dept Radiol, Radiol, Los Angeles, CA USA
[13] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2001
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
    Lim, Michael
    Weller, Michael
    Idbaih, Ahmed
    Steinbach, Joachim
    Finocchiaro, Gaetano
    Raval, Raju R.
    Ansstas, George
    Baehring, Joachim
    Taylor, Jennie W.
    Honnorat, Jerome
    Petrecca, Kevin
    De Vos, Filip
    Wick, Antje
    Sumrall, Ashley
    Sahebjam, Solmaz
    Mellinghoff, Ingo K.
    Kinoshita, Masashi
    Roberts, Mustimbo
    Slepetis, Ruta
    Warad, Deepti
    Leung, David
    Lee, Michelle
    Reardon, David A.
    Omuro, Antonio
    NEURO-ONCOLOGY, 2022, 24 (11) : 1935 - 1949
  • [2] Delineation of MGMT promoter hypermethylation as a predictive biomarker for the A071102 clinical trial of veliparib combined with temozolomide (TMZ) using patient-derived xenograft (PDX) GBM models.
    Sarkaria, Jann Nagina
    Gupta, Shiv
    Kizilbash, Sani Haider
    Carlson, Brett
    Mladek, Ann
    Bakken, Katrina
    Schroeder, Mark A.
    Decker, Paul A.
    Sulman, Erik P.
    Eckel-Passow, Jeanette
    Kitange, Gaspar
    Jenkins, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
    Omuro, Antonio
    Brandes, Alba A.
    Carpentier, Antoine F.
    Idbaih, Ahmed
    Reardon, David A.
    Cloughesy, Timothy
    Sumrall, Ashley
    Baehring, Joachim
    van den Bent, Martin
    Bahr, Oliver
    Lombardi, Giuseppe
    Mulholland, Paul
    Tabatabai, Ghazaleh
    Lassen, Ulrik
    Sepulveda, Juan Manuel
    Khasraw, Mustafa
    Vauleon, Elodie
    Muragaki, Yoshihiro
    Di Giacomo, Anna Maria
    Butowski, Nicholas
    Roth, Patrick
    Qian, Xiaozhong
    Fu, Alex Z.
    Liu, Yanfang
    Potter, Von
    Chalamandaris, Alexandros-Georgios
    Tatsuoka, Kay
    Lim, Michael
    Weller, Michael
    NEURO-ONCOLOGY, 2023, 25 (01) : 123 - 134
  • [4] A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients with an Unmethylated MGMT Gene Promoter
    Faye, M. D.
    Sabri, S.
    De Robles, P.
    Agnihotram, R.
    Torres-Vasquez, A.
    Panet-Raymond, V.
    Shenouda, G.
    Souhami, L.
    Esaw, J.
    Abdulkarim, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S169 - S169
  • [5] Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
    Faye, Mame Daro
    Easaw, Jacob
    De Robles, Paula
    Agnihotram, Raman
    Torres-Vasquez, Alexander
    Lamonde, Frederic
    Petrecca, Kevin
    Owen, Scott
    Panet-Raymond, Valerie
    Shenouda, George
    Souhami, Luis
    Azam, Maryam
    Hossain, Bushra
    Alkass, Jad
    Sabri, Siham
    Abdulkarim, Bassam
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [6] A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).
    Khasraw, Mustafa
    McDonald, Kerrie Leanne
    Rosenthal, Mark
    Lwin, Zarnie
    Ashley, David M.
    Wheeler, Helen
    Barnes, Elizabeth
    Foote, Matthew C.
    Koh, Eng-Siew
    Sulman, Erik P.
    Back, Michael
    Buckland, Michael
    Sim, Hao-Wen
    Fisher, Lauren
    Leonard, Robyn
    Hall, Merryn
    Yip, Sonia
    Simes, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
    Sim, Hao-Wen
    McDonald, Kerrie L.
    Lwin, Zarnie
    Barnes, Elizabeth H.
    Rosenthal, Mark
    Foote, Matthew C.
    Koh, Eng-Siew
    Back, Michael
    Wheeler, Helen
    Sulman, Erik P.
    Buckland, Michael E.
    Fisher, Lauren
    Leonard, Robyn
    Hall, Merryn
    Ashley, David M.
    Yip, Sonia
    Simes, John
    Khasraw, Mustafa
    NEURO-ONCOLOGY, 2021, 23 (10) : 1736 - 1749
  • [8] Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
    Supriya Mallick
    Haresh Kunhiparambath
    Subhash Gupta
    Rony Benson
    Seema Sharma
    M. A. Laviraj
    Ashish Datt Upadhyay
    Pramod Kumar Julka
    Dayanand Sharma
    Goura Kishor Rath
    Journal of Neuro-Oncology, 2018, 140 : 75 - 82
  • [9] Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)
    Mallick, Supriya
    Kunhiparambath, Haresh
    Gupta, Subhash
    Benson, Rony
    Sharma, Seema
    Laviraj, M. A.
    Upadhyay, Ashish Datt
    Julka, Pramod Kumar
    Sharma, Dayanand
    Rath, Goura Kishor
    JOURNAL OF NEURO-ONCOLOGY, 2018, 140 (01) : 75 - 82
  • [10] Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
    Wick, Wolfgang
    Gorlia, Thierry
    Bady, Pierre
    Platten, Michael
    van den Bent, Martin J.
    Taphoorn, Martin J. B.
    Steuve, Jonathan
    Brandes, Alba A.
    Hamou, Marie-France
    Wick, Antje
    Kosch, Markus
    Weller, Michael
    Stupp, Roger
    Roth, Patrick
    Golfinopoulos, Vassilis
    Frenel, Jean-Sebastien
    Campone, Mario
    Ricard, Damien
    Marosi, Christine
    Villa, Salvador
    Weyerbrock, Astrid
    Hopkins, Kirsten
    Homicsko, Krisztian
    Lhermitte, Benoit
    Pesce, Gianfranco
    Hegi, Monika E.
    CLINICAL CANCER RESEARCH, 2016, 22 (19) : 4797 - 4806
12345